NasdaqGM:FULCPharmaceuticals
Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options
In June 2026, Fulcrum Therapeutics announced it would discontinue development of its investigational sickle cell disease drug pociredir after FDA feedback linked malignancy risks across PRC2 inhibitors and simultaneously began a broad review of options such as mergers, acquisitions, or other transactions while cutting costs to conserve its US$333.3 million in cash and securities as of March 31, 2026.
This marks a sharp shift for a company whose lead asset had previously shown encouraging...